ŠTROS, Michal, Eva VOLFOVÁ POLANSKÁ, Tereza HLAVÁČOVÁ and Petr SKLÁDAL. Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19. Biomolecules. Basel: MDPI, 2022, vol. 12, No 4, p. 1-11. ISSN 2218-273X. Available from: https://dx.doi.org/10.3390/biom12040544.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19
Authors ŠTROS, Michal (guarantor), Eva VOLFOVÁ POLANSKÁ, Tereza HLAVÁČOVÁ (203 Czech Republic, belonging to the institution) and Petr SKLÁDAL (203 Czech Republic, belonging to the institution).
Edition Biomolecules, Basel, MDPI, 2022, 2218-273X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10601 Cell biology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.500
RIV identification code RIV/00216224:14310/22:00126405
Organization unit Faculty of Science
Doi http://dx.doi.org/10.3390/biom12040544
UT WoS 000787419100001
Keywords in English HMGB1; plasma/serum; ELISA; EMSA; immunosensor; COVID-19
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Marie Šípková, DiS., učo 437722. Changed: 10/8/2022 14:29.
Abstract
Extracellular HMGB1 protein is known to induce inflammatory responses leading to an inflammatory storm. The outbreak of the Severe Acute Respiratory Syndrome COVID-19 due to the SARS-CoV-2 virus has resulted in a huge health concern worldwide. Recent data revealed that plasma/serum HMGB1 levels of patients suffering from inflammation-mediated disorders-such as COVID-19, cancer, and autoimmune disorders-correlate positively with disease severity and vice versa. A late release of HMGB1 in sepsis suggests the existence of a wide therapeutic window for treating sepsis. Rapid and accurate methods for the detection of HMGB1 levels in plasma/serum are, therefore, of great importance for monitoring the occurrence, treatment success, and survival prediction of patients with inflammation-mediated diseases. In this review, we briefly explain the role of HMGB1 in the cell, and particularly the involvement of extracellular HMGB1 (released from the cells) in inflammation-mediated diseases, with an emphasis on COVID-19. The current assays to measure HMGB1 levels in human plasma-Western blotting, ELISA, EMSA, and a new approach based on electrochemical immunosensors, including some of our preliminary results-are presented and thoroughly discussed.
Links
NU20-08-00106, research and development projectName: Elektrochemický imunodetektor pro detekci HMGB1 v séru pacientů s různými formami leukémie: metoda pro rychlé zhodnocení úspěšnosti léčby
Investor: Ministry of Health of the CR, Subprogram 1 - standard
PrintDisplayed: 31/7/2024 00:23